All In Biotech

Drug Trial Radar · NCT04092686

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 464 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

464

Actual

Start

Oct 14, 2019

Primary completion

Jun 14, 2023

Study completion Jun 14, 2023

Sponsor

Sponsor type
Industry
First posted
Sep 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 18 -65 years old who have been diagnosed with schizophrenia. This study will be conducted in 60 locations world wide. The study will last up to nine (9) weeks.

Conditions

  • Schizophrenia

Interventions

  • SEP-363856 75mgDrug

    SEP-363856 75mg tablet dosed once daily

  • SEP-363856 100mgDrug

    SEP-363856 100mg tablet dosed once daily

  • PlaceboDrug

    Placebo tablet dosed once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in PANSS Total Score at Week 6Time frame: Baseline, Week 6

Locations

53 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Rogers, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Bellflower, California

  • Research Site

    Culver City, California

  • Research Site

    Long Beach, California

  • Research Site

    San Diego, California

  • Research Site

    Sherman Oaks, California

  • Research Site

    Hollywood, Florida

  • Research Site

    Miami Springs, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Lake Charles, Louisiana

  • Research Site

    Gaithersburg, Maryland

  • Research Site

    St Louis, Missouri

  • Research Site

    Marlton, New Jersey

  • Research Site

    New York, New York

  • Research Site

    Richardson, Texas

  • Research Site

    Burgas, Bulgaria

  • Research Site

    Kardzhali, Bulgaria

  • Research Site

    Novi Iskar, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Zagreb, Croatia

  • Research Site

    Daugavpils, Latvia

  • Research Site

    Riga, Latvia

  • Research Site

    Strenči, Latvia

  • Research Site

    Arkhangelsk, Russia

  • Research Site

    Engel's, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saratov, Russia

  • Research Site

    Saratov, Russia

  • Research Site

    Stavropol, Russia

  • Research Site

    Tomsk, Russia

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.